Gastroesophageal Reflux Disease

This study is currently active

Gastroesophageal reflux disease (GERD) is prevalent globally and represents one of the most common gastrointestinal diseases. Per the Montreal definition, GERD is a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications. The term GERD covers a spectrum of conditions, including NERD, erosive esophagitis (EE), and Barrett’s esophagus. When defining GERD as the presence of at least weekly heartburn and/or regurgitation, epidemiological studies reported prevalence estimates of 18.1% to 27.8%, 8.8% to 25.9%, and 2.5% to 7.8% in North America, Europe, and East Asia, respectively.

This trial is a medication approved in Japan and looking for approval in the US. Study is 28 weeks with 7 office visits. The study will require and endoscopy if screening is passed. Endoscopy is when a tube is put into the esophagus to rule on ulcers or cancer. No cost for procedures and compensation up to $785.

Participate in a Study

Submit the form and a clinical study expert will get in touch with you.

Want to know more about our clinical trials?